Skip to main content

Hikma Pharmaceuticals Plc Value Stock - Dividend - Research Selection

Hikma Pharmaceuticals Plc

ISIN: GB00B0LCW083, WKN: A0HG69

Market price date: 08.01.2021
Market price: 36,20 USD




Hikma Pharmaceuticals Plc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 01-03-2020
Cash flow
Net operating cash flow 472.000.000
Capital Expenditures -119.000.000
Free cash flow 353.000.000
Balance sheet
Total Equity 2.117.000.000
Liabilities & Shareholders equity 3.930.000.000
Income statement
Net income 486.000.000
Eps (diluted) 2,010
Diluted shares outstanding 241.791.000
Net sales/revenue 2.207.000.000

Fundamental ratios calculated on: 08-01-2021

Ratios
Key figures 08-01-2021
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI12,37
ROE53,87
Income statement
P/E18,01
Div. Yield0,00%
P/B0,00
P/S3,97


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolHKMPF
Market Capitalization8.752.834.560,00 USD
CountryUnited Kingdom
IndicesFTSE 100
SectorsPharma
Raw Data SourceIFRS in Millionen USD
Stock Split
Internetwww.hikma.com


Description of the company

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas. This segment\'s principal products include Amoclan, Blopress, Omnicef, Prograf, and Suprax. The Injectables segment markets 201 products in 571 dosage strengths and forms for anti-infective, cardiovascular, diabetes, controlled substances, gastro-intestinal, oncology, CNS, respiratory, and miscellaneous therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. This segment\'s principal products include fentanyl, glycopyrrolate, neostigmine, nicardipine, and thiotepa. The Generics segment provides 109 products in 375 dosage strengths and forms for therapeutic areas, including anti-infective, controlled substances, oncology, and miscellaneous therapeutic areas. This segment\'s principal products include amoxicillin, buprenorphine, butalbital, acetaminophen and caffeine, colchicine, and fluticasone. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.hikma.com